Overview

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Status:
Active, not recruiting
Trial end date:
2025-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Collaborator:
Takeda Development Center Americas, Inc.
Treatments:
Vedolizumab